<?xml version="1.0" encoding="iso-8859-1" standalone="no"?>
<!DOCTYPE GmsArticle SYSTEM "http://www.egms.de/dtd/2.0.34/GmsArticle.dtd">
<GmsArticle xmlns:xlink="http://www.w3.org/1999/xlink">
  <MetaData>
    <Identifier>26doc139</Identifier>
    <IdentifierDoi>10.3205/26doc139</IdentifierDoi>
    <IdentifierUrn>urn:nbn:de:0183-26doc1391</IdentifierUrn>
    <ArticleType>Meeting Abstract</ArticleType>
    <TitleGroup>
      <Title language="en">Reversible 20&#47;200 vision loss in malignant hypertension: 8-day resolution of exudative maculopathy and disc edema</Title>
    </TitleGroup>
    <CreatorList>
      <Creator>
        <PersonNames>
          <Lastname>Dhrami</Lastname>
          <LastnameHeading>Dhrami</LastnameHeading>
          <Firstname>Elona</Firstname>
          <Initials>E</Initials>
        </PersonNames>
        <Address>
          <Affiliation>University of North Dakota, Grand Forks, USA</Affiliation>
        </Address>
        <Creatorrole corresponding="no" presenting="no">author</Creatorrole>
      </Creator>
      <Creator>
        <PersonNames>
          <Lastname>Gavazi</Lastname>
          <LastnameHeading>Gavazi</LastnameHeading>
          <Firstname>Jona</Firstname>
          <Initials>J</Initials>
        </PersonNames>
        <Address>
          <Affiliation>Brown University, Providence, USA</Affiliation>
        </Address>
        <Creatorrole corresponding="no" presenting="no">author</Creatorrole>
      </Creator>
    </CreatorList>
    <PublisherList>
      <Publisher>
        <Corporation>
          <Corporatename>German Medical Science GMS Publishing House</Corporatename>
        </Corporation>
        <Address>D&#252;sseldorf</Address>
      </Publisher>
    </PublisherList>
    <SubjectGroup>
      <SubjectheadingDDB>610</SubjectheadingDDB>
    </SubjectGroup>
    <DatePublishedList>
      <DatePublished>20260617</DatePublished>
    </DatePublishedList>
    <Language>engl</Language>
    <License license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
      <AltText language="en">This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License.</AltText>
      <AltText language="de">Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung).</AltText>
    </License>
    <SourceGroup>
      <Meeting>
        <MeetingId>M0651</MeetingId>
        <MeetingSequence>139</MeetingSequence>
        <MeetingName></MeetingName>
        <MeetingTitle>38. Internationaler Kongress der Deutschen Ophthalmochirurgie (DOC)</MeetingTitle>
        <MeetingSession>Retina</MeetingSession>
        <MeetingCity>N&#252;rnberg</MeetingCity>
        <MeetingDate>
          <DateFrom>20260618</DateFrom>
          <DateTo>20260620</DateTo>
        </MeetingDate>
      </Meeting>
    </SourceGroup>
    <ArticleNo>EPO 6.8</ArticleNo>
  </MetaData>
  <OrigData>
    <TextBlock name="Text" linked="yes">
      <MainHeadline>Text</MainHeadline><Pgraph><Mark1>Purpose:</Mark1> To report a case of profound bilateral vision loss secondary to malignant hypertension and to highlight the rapid functional and anatomical recovery following emergent systemic stabilization.</Pgraph><Pgraph><Mark1>Methods:</Mark1> A 48-year-old female presented with acute bilateral vision loss (20&#47;200 OU). Clinical examination and multimodal imaging revealed Grade IV hypertensive retinopathy characterized by massive optic nerve head edema, significant intraretinal exudation, and hyperreflective lipid deposits in the macular region. Point-of-care vitals confirmed malignant hypertension (215&#47;123 mmHg, heart rate 68 BPM). Management included emergent referral for systemic blood pressure control and initiation of topical aqueous suppressants to mitigate the risk of hypertensive-related vaso-occlusive events.</Pgraph><Pgraph><Mark1>Results:</Mark1> The patient was hospitalized for controlled reduction of systemic blood pressure. Following medical stabilization, the patient experienced a steady improvement in visual function. Within 8 days, OCT imaging confirmed that the intraretinal fluid and macular exudation had largely regressed. Best-corrected visual acuity (BCVA) restored from 20&#47;200 to 20&#47;20 OU. Subsequent follow-up demonstrated the gradual absorption of the remaining lipid deposits and the return of normal optic nerve head morphology.</Pgraph><Pgraph><Mark1>Conclusion:</Mark1> This case illustrates that severe visual impairment from malignant hypertension can be largely reversible with prompt systemic management. While the initial presentation of 20&#47;200 visual acuity bilaterally and significant exudative changes is clinically concerning, it highlights the retina&#8217;s inherent capacity for recovery once hemodynamic stress is relieved. It underscores the role of the eye as a critical sentinel for systemic health and emphasizes the importance of ophthalmic triage in the multidisciplinary management of hypertensive crises.</Pgraph></TextBlock>
    <Media>
      <Tables>
        <NoOfTables>0</NoOfTables>
      </Tables>
      <Figures>
        <NoOfPictures>0</NoOfPictures>
      </Figures>
      <InlineFigures>
        <NoOfPictures>0</NoOfPictures>
      </InlineFigures>
      <Attachments>
        <NoOfAttachments>0</NoOfAttachments>
      </Attachments>
    </Media>
  </OrigData>
</GmsArticle>